Affiliation:
1. Tsuchiya General Hospital, 3-30 Nakajima-cho Naka-ku, Hiroshima 730-8655, Japan
Abstract
The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5–58 kDa, and new classifications of “small-middle 0.5–15 kDa,” “medium-middle 15–25 kDa,” and “large-middle 25–58 kDa” were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.
Reference45 articles.
1. The technique of continous hemodialysis;Scribner;Trans. Am. Soc. Artif. Intern. Organs,1960
2. “On line” preparation of sterile pyrogen-free electrolyte solution;Henderson;Trans. Am. Soc. Artif. Intern. Organs,1978
3. Regulatory Considerations for Hemodiafiltration in the United States;Ward;Clin. J. Am. Soc. Nephrol.,2018
4. Clinical experience with a new hemodiafiltration (HDF) system;Rindi;ASAIO Trans.,1988
5. Global prevalent use, trends and practices in haemodiafiltration;Canaud;Nephrol. Dial. Transplant.,2020